• Je něco špatně v tomto záznamu ?

Quality by Design as a risk-based strategy in pharmaceutical analysis: Development of a liquid chromatography-tandem mass spectrometry method for the determination of nintedanib and its impurities

B. Pasquini, S. Orlandini, S. Furlanetto, R. Gotti, M. Del Bubba, F. Boscaro, B. Bertaccini, M. Douša, G. Pieraccini,

. 2020 ; 1611 (-) : 460615. [pub] 20191010

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20005778

Nintedanib (NIN) is a tyrosine kinase inhibitor recently approved for the treatment of idiopathic pulmonary fibrosis. As a new drug, no monograph is available so far in official compendia. A liquid chromatography-tandem mass spectrometry method is presented for the simultaneous determination of NIN and its seven potential impurities. The risk-based approach of Analytical Quality by Design was applied in method development. The critical method parameters (CMPs) were the type of organic solvent in the mobile phase, formic acid percentage, column flow rate, oven temperature, gradient slope of organic eluent. The critical method attributes (CMAs) were selected as analysis time and selectivity between the main compound NIN and the adjacent peaks. Design of Experiments methodology was effectively employed for establishing the relationship between the CMPs and the CMAs. In the scouting step, a Restek Ultra AQ C18 (100 × 2.1 mm, 2.7 µm) core-shell column was selected, and then the effects of different levels of the five CMPs on the CMAs were evaluated by means of a 35//16 symmetric screening matrix. A Box-Behnken Design made it possible to obtain detailed maps of predicted CMAs throughout the investigated experimental domain, pointing out the presence of interaction and quadratic effects. The probability of meeting the specifications for the CMAs was calculated by Monte-Carlo simulations, performing a risk analysis and drawing risk of failure maps, which were used to visualize and define the method operable design region (MODR) with a probability π ≥ 90%. The final working conditions (enclosing the MODR interval) were as follows: methanol as organic solvent; formic acid percentage, 0.15% v/v; flow rate, 0.40 mL min-1 (0.37-0.43 mL min-1); oven temperature, 40 °C (38-40 °C); gradient slope of organic eluent, 14.00% eluent B min-1 (12.85-15.15% eluent B min-1). The resulting analysis time was about 10 min. Validation was carried out according to International Council for Harmonisation guidelines and the optimized method was applied to the analysis of NIN soft capsules for quality control purposes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005778
003      
CZ-PrNML
005      
20200518132105.0
007      
ta
008      
200511s2020 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.chroma.2019.460615 $2 doi
035    __
$a (PubMed)31630831
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Pasquini, Benedetta $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019 Sesto Fiorentino, Florence, Italy. Electronic address: benedetta.pasquini@unifi.it.
245    10
$a Quality by Design as a risk-based strategy in pharmaceutical analysis: Development of a liquid chromatography-tandem mass spectrometry method for the determination of nintedanib and its impurities / $c B. Pasquini, S. Orlandini, S. Furlanetto, R. Gotti, M. Del Bubba, F. Boscaro, B. Bertaccini, M. Douša, G. Pieraccini,
520    9_
$a Nintedanib (NIN) is a tyrosine kinase inhibitor recently approved for the treatment of idiopathic pulmonary fibrosis. As a new drug, no monograph is available so far in official compendia. A liquid chromatography-tandem mass spectrometry method is presented for the simultaneous determination of NIN and its seven potential impurities. The risk-based approach of Analytical Quality by Design was applied in method development. The critical method parameters (CMPs) were the type of organic solvent in the mobile phase, formic acid percentage, column flow rate, oven temperature, gradient slope of organic eluent. The critical method attributes (CMAs) were selected as analysis time and selectivity between the main compound NIN and the adjacent peaks. Design of Experiments methodology was effectively employed for establishing the relationship between the CMPs and the CMAs. In the scouting step, a Restek Ultra AQ C18 (100 × 2.1 mm, 2.7 µm) core-shell column was selected, and then the effects of different levels of the five CMPs on the CMAs were evaluated by means of a 35//16 symmetric screening matrix. A Box-Behnken Design made it possible to obtain detailed maps of predicted CMAs throughout the investigated experimental domain, pointing out the presence of interaction and quadratic effects. The probability of meeting the specifications for the CMAs was calculated by Monte-Carlo simulations, performing a risk analysis and drawing risk of failure maps, which were used to visualize and define the method operable design region (MODR) with a probability π ≥ 90%. The final working conditions (enclosing the MODR interval) were as follows: methanol as organic solvent; formic acid percentage, 0.15% v/v; flow rate, 0.40 mL min-1 (0.37-0.43 mL min-1); oven temperature, 40 °C (38-40 °C); gradient slope of organic eluent, 14.00% eluent B min-1 (12.85-15.15% eluent B min-1). The resulting analysis time was about 10 min. Validation was carried out according to International Council for Harmonisation guidelines and the optimized method was applied to the analysis of NIN soft capsules for quality control purposes.
650    _2
$a chromatografie kapalinová $x metody $7 D002853
650    _2
$a indoly $x analýza $x chemie $7 D007211
650    _2
$a metoda Monte Carlo $7 D009010
650    _2
$a pravděpodobnost $7 D011336
650    _2
$a řízení kvality $7 D011786
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a riziko $7 D012306
650    _2
$a rozpouštědla $7 D012997
650    _2
$a tandemová hmotnostní spektrometrie $x metody $7 D053719
655    _2
$a časopisecké články $7 D016428
700    1_
$a Orlandini, Serena $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019 Sesto Fiorentino, Florence, Italy. Electronic address: serena.orlandini@unifi.it.
700    1_
$a Furlanetto, Sandra $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019 Sesto Fiorentino, Florence, Italy. Electronic address: sandra.furlanetto@unifi.it.
700    1_
$a Gotti, Roberto $u Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy. Electronic address: roberto.gotti@unibo.it.
700    1_
$a Del Bubba, Massimo $u Department of Chemistry "U. Schiff", University of Florence, Via U. Schiff 6, Via della Lastruccia 3-13, 50019 Sesto Fiorentino, Florence, Italy. Electronic address: massimo.delbubba@unifi.it.
700    1_
$a Boscaro, Francesca $u Mass Spectrometry Center (CISM), University of Florence, Viale G. Pieraccini 6, 50139 Florence, Italy. Electronic address: francesca.boscaro@unifi.it.
700    1_
$a Bertaccini, Bruno $u Department of Statistics, Informatics and Applications "Giuseppe Parenti" (DiSIA), University of Florence, Viale Morgagni 59, 50134 Florence, Italy. Electronic address: bruno.bertaccini@unifi.it.
700    1_
$a Douša, Michal $u Zentiva, k.s. Praha, U Kabelovny 130, 102 37 Praha 10, Czech Republic. Electronic address: michal.dousa@seznam.cz.
700    1_
$a Pieraccini, Giuseppe $u Mass Spectrometry Center (CISM), University of Florence, Viale G. Pieraccini 6, 50139 Florence, Italy. Electronic address: giuseppe.pieraccini@unifi.it.
773    0_
$w MED00004962 $t Journal of chromatography. A $x 1873-3778 $g Roč. 1611, č. - (2020), s. 460615
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31630831 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200518132105 $b ABA008
999    __
$a ok $b bmc $g 1524636 $s 1095834
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 1611 $c - $d 460615 $e 20191010 $i 1873-3778 $m Journal of chromatography. A, Including electrophoresis and other separation methods $n J Chromatogr A $x MED00004962
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...